Using liraglutide in people with obesity and prediabetes is a valuable strategy for weight loss, but improvements are greater with caloric restriction alone, suggest study results.

Treatment with the GLP-1 receptor agonist liraglutide is associated with a reduction in cardiac adipose tissue volume among people with type 2 diabetes, suggests a secondary analysis of data from the LiraFlame trial.

The addition of liraglutide rather than extra oral antidiabetic drugs may offer more sustained glycemic control for people with type 2 diabetes who have inadequate control with metformin, suggest findings of the international LIRA-PRIME study.

Findings from a phase 3 randomized crossover trial suggest that 7 weeks of treatment with liraglutide may improve forced vital capacity among people with type 2 diabetes and impaired lung function.

Phase 2 study results suggest that add-on treatment with an anti-IL-21 antibody plus liraglutide could preserve endogenous insulin secretion in people with recent-onset type 1 diabetes.

A post-hoc analysis of the LEADER trial suggests that liraglutide reduces cardiovascular risk in people with type 2 diabetes regardless of whether they have heart failure.

Findings from the SUSTAIN 10 trial show that semaglutide results in better glycemic control than liraglutide when added to oral antidiabetic drugs in people with type 2 diabetes.

Findings from the NewLira trial suggest that addition of the glucagon-like peptide-1 receptor agonist liraglutide to insulin treatment may preserve postprandial insulin secretion among adults with newly diagnosed type 1 diabetes.

Registry data from Denmark and Sweden uphold the cardioprotective effects of liraglutide observed in randomized trials, with the strongest effects seen in patients with established cardiovascular disease.

Tamborlane believes that slow liraglutide dose titration might explain this finding.

The LEADER investigators report that treatment with the glucagon-like peptide-1 receptor agonist liraglutide may be of particular benefit in the oldest patients with type 2 diabetes.

Findings from the GRAVITAS trial indicate that use of the GLP-1 receptor agonist liraglutide alongside a diet and physical activity intervention may improve glycemic control among people with persistent or recurrent type 2 diabetes after bariatric surgery.

Factors including bodyweight and treatment duration predict response to liraglutide in patients with type 2 diabetes treated in clinical practice, report researchers.

Patients with type 2 diabetes who are treated with semaglutide experience greater improvements in glycemic control than those given liraglutide, but at the cost of a higher risk for gastrointestinal adverse events, researchers report.

Obese patients with type 2 diabetes who receive treatment intensification with liraglutide may have better glycemic control than those given basal insulin, researchers report.

A post-hoc analysis of the LEADER trial indicates that liraglutide treatment may reduce the risk for severe hypoglycemia among patients with type 2 diabetes.

The cardioprotective effects of liraglutide apply to patients with chronic kidney disease as well as those with established cardiovascular disease, show two post-hoc analyses of the LEADER trial.

Taking the glucagon-like peptide-1 receptor agonist liraglutide does not increase patients’ risk for acute pancreatitis during more than 3 years of treatment, show two reports analyzing the LEADER and SCALE trials.